Keywords: astrazeneca, evaluate, atacand, cognitive, decline, reveals, insight
AstraZeneca to evaluate Atacand in cognitive decline, reveals INSIGHT data
Article | 08 June 2000
AstraZeneca has initiated a large clinical trial of itsAT1-receptor blocker Atacand/lopress (candesartan) in 4,964 elderly patients with mild hypertension. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
